BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36468941)

  • 1. Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity.
    Meng F; Li L; Zhang Z; Lin Z; Zhang J; Song X; Xue T; Xing C; Liang X; Zhang X
    J Extracell Vesicles; 2022 Dec; 11(12):e12289. PubMed ID: 36468941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
    Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
    Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
    Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
    Kojima T; Yamazaki K; Tamura Y; Ogura S; Tani K; Konishi J; Shinagawa N; Kinoshita I; Hizawa N; Yamaguchi E; Dosaka-Akita H; Nishimura M
    Hum Gene Ther; 2003 May; 14(8):715-28. PubMed ID: 12804136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
    Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Lin Z; Meng F; Ma Y; Zhang C; Zhang Z; Yang Z; Li Y; Hou L; Xu Y; Liang X; Zhang X
    Bioact Mater; 2024 Feb; 32():12-27. PubMed ID: 37790917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
    Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
    Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.
    Wu Y; Feng L
    Expert Opin Drug Deliv; 2023 Mar; 20(3):323-333. PubMed ID: 36634017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy.
    Ye X; Liang X; Chen Q; Miao Q; Chen X; Zhang X; Mei L
    ACS Nano; 2019 Mar; 13(3):2956-2968. PubMed ID: 30789699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
    Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
    Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy.
    Ji P; Sun W; Zhang S; Xing Y; Wang C; Wei M; Li Q; Ji G; Yang G
    Adv Sci (Weinh); 2023 Aug; 10(22):e2301789. PubMed ID: 37222047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
    Klein C; Bueler H; Mulligan RC
    J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
    Blass E; Ott PA
    Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neo-intline: integrated pipeline enables neoantigen design through the in-silico presentation of T-cell epitope.
    Li B; Jing P; Zheng G; Pi C; Zhang L; Yin Z; Xu L; Qiu J; Gu H; Qiu T; Fang J
    Signal Transduct Target Ther; 2023 Oct; 8(1):397. PubMed ID: 37848417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of fusion gene mGM-CSF/hIL-2 to specific immunotherapy induced by hepatic tumor cell vaccine].
    Yang W; Guo C; Liu QG
    Ai Zheng; 2008 Feb; 27(2):149-54. PubMed ID: 18279611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.